Canmab (Trastuzumab Vials) 440mg

Canmab (Trastuzumab) 440mg vials are a targeted therapy used in cancer treatment. This monoclonal antibody works by binding to HER2 receptors to slow tumor growth. Suitable for patients with HER2-positive cancers. Short-term storage guidance may apply.

Strength

440mg

Manufacturer / TM Owner

Biocon Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trastuzumab is primarily used to treat HER2-positive breast and gastric cancers. It may be prescribed before or after surgery, or in combination with chemotherapy. This medication is also used for metastatic cancer management. Patients should discuss specific treatment plans with their healthcare provider.

Side Effects

Trastuzumab works by targeting cancer cells with HER2 receptors, helping to slow their growth. Patients may experience fatigue or mild infusion-related reactions during treatment. Regular monitoring is recommended to assess response and manage any side effects.

Precautions & Warnings

Trastuzumab should be handled and administered by trained professionals in a clinical setting. Patients with known heart conditions should inform their doctor before starting treatment. Pregnant or breastfeeding individuals should avoid this medication due to potential risks.

Avoid Interactions

Trastuzumab may interact with other medications, including certain chemotherapy drugs and heart medications. Patients should inform their doctor about all prescription, over-the-counter, and herbal products they are using. Avoid live vaccines during treatment unless approved by a healthcare provider.

Frequently Asked Questions

Canmab is used to treat HER2-positive breast and gastric cancers by targeting cancer cells.

Trastuzumab is given as an intravenous infusion in a clinical setting by healthcare professionals.

Trastuzumab is not recommended during pregnancy due to potential risks to the fetus.

Common effects may include fatigue, infusion reactions, or heart-related symptoms.

Trastuzumab is the generic name; Canmab is a branded version of the medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.